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Abstract: Premature ejaculation (PE) is the most common male sexual disorder, estimated to 
affect up to 30% of men. Over the past one or two decades, clinical investigators have partici-
pated in an increasing number of studies that are helping in our understanding of PE, which will 
undoubtedly facilitate future treatments. Apart from a number of behavioral approaches, the 
treatment of PE consists of primarily off-label use of oral selective serotonin reuptake inhibitors 
(SSRIs) via either on-demand or daily delivery. However, various undesirable side-effects of 
these medications have led researchers to search for and develop new therapeutic approaches 
for PE. Dapoxetine is a short-acting SSRI developed speciﬁ  cally for the treatment of PE. Early 
trials with dapoxetine have documented successful outcomes without serious short- or long-
term side-effects. This review addresses the deﬁ  nition, classiﬁ  cation, diagnosis, physiology, and 
neurobiopathology of PE, and evaluates therapeutic strategies with novel treatments for PE.
Keywords: dapoxetine, premature ejaculation, selective serotonin reuptake inhibitor, sildenaﬁ  l, 
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Introduction
Premature ejaculation (PE) is the most common male sexual disorder, and is estimated 
to affect up to 30% of men worldwide (Goldstein 2003). PE, unlike erectile dysfunction 
(ED), affects men of all ages equally, from 18-year-olds to the elderly. However, both 
PE and ED coexist, and often PE can masquerade or be misdiagnosed as ED in many 
men. This is, in part, due to the lack of knowledge about PE, the absence of perform-
ing a careful history, and the non-existence of diagnostic tools for PE (Montague et al 
2004). Despite its high prevalence and recognized adverse effects on men’s quality 
of life, only recently has attention been focused on investigating the causes of PE and 
developing new therapeutic strategies.
Over the past 20–30 years, clinical investigators have participated in a growing 
number of controlled studies that are developing our basic understanding about PE 
in ways that will facilitate its future treatment (Waldinger 2002). The emergence of 
well-conducted clinical trials has created a greater understanding of the prevalence 
of PE, its etiology and pathophysiology, and, additionally, its impact on patient and 
partner quality of life. However, there are currently no regulatory or FDA-approved 
pharmacological therapies for treating PE.
This communication will focus on the prevalence, etiology, pathophysiology, and 
the current treatment options for PE. More speciﬁ  cally, a novel selective serotonin 
reuptake inhibitor (SSRI), dapoxetine, will be evaluated for its pharmacokinetics, 
efﬁ  cacy, and safety record in light of available preclinical and clinical data.
Deﬁ  nition
Though PE is a non-life-threatening condition, like ED, it has a serious impact on patient 
and partner quality of life. The lack of agreement on a single precise deﬁ  nition of PE Therapeutics and Clinical Risk Management 2007:3(2) 278
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has hampered scientiﬁ  c research on the causes and manage-
ment of PE (McMahon et al 2004). Various deﬁ  nitions of PE 
have been used by different researchers, and include partner 
satisfaction, male voluntary control, duration of ejaculatory 
latency, and number of intravaginal thrusts (Jannini et al 
2002). A universally accepted deﬁ  nition of PE has yet to be 
established. Masters and Johnson proposed one of the earliest 
deﬁ  nitions of PE, as the inability to delay ejaculation long 
enough for the woman to achieve orgasm 50% of the time, 
assuming the PE was the sole cause of the female anorgasmia 
(Masters and Johnson 1970). Kaplan ﬁ  rst suggested that PE 
was primarily a problem of voluntary control over timing of 
ejaculation, a concept on which most of the current deﬁ  nitions 
are based (Kaplan et al 1974). The Diagnostic and Statistical 
Manual of Mental Disorders, 4th ed (DSM-IV-TR), deﬁ  nes 
PE similarly but has an added emphasis on the emotional 
and interpersonal impact of early ejaculation The American 
Urological Association Guideline on Premature Ejaculation 
deﬁ  nes PE as “…ejaculation that occurs sooner than desired, 
either before or shortly after penetration, causing distress to 
either one or both partners” (Montague et al 2004).
In 1994, Waldinger et al (1994) introduced and deﬁ  ned 
intravaginal ejaculatory latency time (IELT) as an objective 
measure for ejaculation time. The IELT is deﬁ  ned as the 
time from vaginal intromission to intravaginal ejaculation. 
A distinct advantage of using the IELT is its clear starting 
and end points, which are important for comparative research 
purposes. An ejaculation that occurs before intromission has 
an IELT rating of 0. The range of IELT used to identify PE 
varies in most studies from 1 to 7 minutes, even though no 
well-controlled studies have been undertaken regarding “nor-
mal” ejaculatory latency times in men across the typical life 
span (Symonds et al 2003). Recently, a large US–European 
cohort study was conducted to analyze the distribution 
of IELT in men from different countries (Waldinger et al 
2005a). This study demonstrated that the shape of the IELT 
distribution is positively skewed, with a median IELT of 5.4 
minutes (range 0.55–44.1 minutes). By applying the 0.5 and 
2.5 percentiles as accepted standards of disease deﬁ  nition 
in a skewed distribution, it appeared that the 0.5 percentile 
equated to an IELT of 0.9 minutes and the 2.5 percentile 
to an IELT of 1.4 minutes. Based on these calculations, 
Waldinger et al (2005c) proposed a deﬁ  nition of lifelong 
PE as a neurobiological dysfunction with an unacceptable 
increase in the risk of developing sexual and psychological 
problems at any time during life. Moreover, it was proposed 
that all men with an IELT of less than 1 minute (belonging to 
the 0.5 percentile) have “deﬁ  nite” PE, while men with IELTs 
between 1 and 1.5 minutes (between 0.5 and 2.5 percentiles) 
have “probable” PE. In addition, the severity of PE (non-
symptomatic, mild, moderate, and severe) was proposed to 
be deﬁ  ned in terms of associated psychological problems. 
The advantage of this deﬁ  nition is the inclusion of both a 
quantitative biological measure, ie, the IELT, as well as the 
inclusion of qualitative psychological measures, ie, amount of 
distress and other psychological parameters, which determine 
the severity of PE. Most current clinical studies of PE use 
IELT as their primary quantitative or objective end-point to 
measure therapeutic efﬁ  cacy (Rowland et al 2004). However, 
subjective patient reported outcome (PRO) measures, such 
as distress, dissatisfaction with sexual intercourse, relation-
ship difﬁ  culties, and perception of ejaculatory control, are 
also vitally important in assessing the condition, and are 
recognized as other indicators for therapeutic efﬁ  cacy and 
ejaculatory function (Rowland et al 2004). 
Classiﬁ  cation of PE
PE has been classiﬁ  ed as either primary (lifelong) that be-
gins when a male ﬁ  rst becomes sexually active or secondary 
(acquired), meaning that a male previously had an acceptable 
level of ejaculatory control and developed the condition later 
in life (Williams 1984; Godpodinoff 1989). Primary PE is 
hypothesized to have a strong biological component with a 
variable psychological contribution. Although psychologi-
cal or situational stressors may contribute to secondary PE, 
certain medical conditions and medications may also be 
associated. Another classiﬁ  cation invokes the terms “global” 
or “universal” (eg, occurs regardless of situation or partner) 
or “situational” (eg, limited to certain situations or partner) 
(McMahon et al 2004). Lifelong (primary) or global PE 
suggests an organic basis that would be optimally treated 
by pharmacotherapy (McMahon et al 2004). Even though 
combined categories of ejaculatory disorders have a reported 
prevalence at some time in a man’s life of up to 75%, their 
causes are complex, comprising psychological, physiologi-
cal, and interpersonal components (Shenassa and Hellstrom 
2001). Upon reviewing PE data, lifelong PE is described as 
a triad of symptoms: ejaculation after few penile thrusts, a 
short IELT (less than 2 minutes), and occurrence of early 
ejaculation during (nearly) every coitus (Waldinger and 
Schweitzer 2005).
Epidemiology
Studies indicate that PE is the most common male sexual 
disorder (Laumann et al 1999; Rowland et al 2004). Accord-
ing to recent studies, 20%–30% of the male population is Therapeutics and Clinical Risk Management 2007:3(2) 279
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affected by PE at any one time, and some researchers believe 
that up to 3 out of 4 men experience PE sometime during 
their lives, although the majority never raise the subject with 
their physician (McMahon 1998). Laumann et al (1999) 
analyzed NHSLS data that included 1410 men and 1749 
women aged 18–59 years, and reported the prevalence of 
PE as approximately 30%. The Global Study of Sexual Atti-
tudes and Behaviors investigated 13,618 men in 19 countries 
aged 40–80 years regarding aspects of sex and relationships 
(Laumann et al 2005). This survey reported that PE occurs 
in nearly 30% of men worldwide. A web-based study by 
Rowland et al (2004) that included 2648 male participants 
reported a prevalence of “possible PE” as 16.2% and “prob-
able PE” as 16.3%. In reviewing the relationship between the 
prevalence of PE and ethnicity, signiﬁ  cant PE was reported 
by 29% of Hispanics, 21% of non-Hispanic blacks, and 16% 
of non-Hispanic whites (Carson et al 2003). In their analysis 
of NHSLS data, Laumann et al (1999) noted that PE was 
more prevalent amongst black men (34%) and white men 
(29%) than among Hispanic men (27%).
Rosen et al (2004) conducted a multinational Internet 
survey among men in Italy, Germany, and the United States. 
Of 8860 men aged 25–70 years who completed questions 1 
through 54 of the survey on general health and sexual atti-
tudes, 26% overall were classiﬁ  ed as having PE. Moreover, 
PE was often associated with ED. Another large survey that 
included 12,134 men from a number of countries documented 
that 7.2% of men met criteria for both PE and ED (Shabsigh 
and Perelman 2005). Overall, 31% of men with PE had ED, 
whereas 44% of men with ED also reported PE.
Physiology of ejaculation
There are three basic mechanisms involved in normal ante-
grade ejaculation: emission, expulsion, and orgasm, and each 
of these components possesses separate neural pathways. 
Ejaculatory dysfunction can result from disruption of any 
point in this cascade of events. Several recent studies have 
clariﬁ  ed some aspects of the physiology of ejaculation. Emis-
sion, which begins with closure of the bladder neck to prevent 
retrograde ﬂ  ow of seminal ﬂ  uid and sperm into the bladder, 
refers to the deposition of seminal ﬂ  uid and sperm from the 
distal epididymis, vas deferens, seminal vesicles, and prostate 
into the posterior urethra (Witt and Grantmyre 1993).
Expulsion refers to the forcible antegrade propulsion 
of semen through the urethral meatus, which is caused by 
contractions of the periurethral and pelvic ﬂ  oor muscles 
and concurrent relaxation of the external urethral sphincter 
and urogenital diaphragm. The sympathetic nervous system 
controls both emission and bladder neck closure, and acts 
through alpha adrenergic receptors. The neural signals that 
lead to ejaculation originate from afferent-sensory stimuli in 
the glans penis and genitalia. These stimuli are transmitted 
by means of the pudendal nerve to higher centers in the brain 
(Witt and Grantmyre 1993). 
Orgasm is a totally separate event, a sensory experi-
ence with considerable subjective variation; it can occur 
independently of ejaculation and even erection. After 
ejaculation, detumescence occurs, followed by a refractory 
period that lengthens with age and with repeated ejacula-
tions. Researchers have demonstrated that the ejaculatory 
mechanism consists of two distinct reﬂ  exes, the glans-vasal 
and the urethromuscular, which are responsible for the 
emission and expulsion phases of ejaculation, respectively 
(Shaﬁ  k 1998). This is consistent with the report by Yang and 
Bradley (1999) of an electrically distinct pathway localized 
to the dorsal nerve of the penis and running from the anterior 
urethra to the bulbocavernous muscle; this is distinct from 
the penile shaft afferent ﬁ  bers. The cortical representation of 
the dorsal nerve of the penis now appears both larger and in 
a different location than was previously conceived (Bradley 
et al 1998).
In a canine electro-ejaculation study, Shafik et al 
(1997) proposed that the observed increase in activity of 
the puborectalis, levator ani, and external anal and exter-
nal urethral sphincter muscles would express the prostatic 
secretions into the posterior urethra, elevate the prostate, and 
partially straighten the prostato-membraneous urethral kink 
that occurs during erection and thereby prevent the leakage 
of feces, ﬂ  atus, and urine during coitus. These investigators 
theorized that the rhythmic external urethral sphincter con-
tractions that occur at the time of ejaculation act as a “suction 
ejection pump”, sucking the genital ﬂ  uid into the posterior 
urethra while being relaxed and expulsing it into the bulbous 
urethra upon contraction.
Neurobiological implications 
of ejaculation
Serotonin is a very important neurotransmitter in the control 
of the ejaculatory reﬂ  ex, with secondary involvement of cho-
linergic, adrenergic, oxytocinergic, and GABAergic neurons. 
The strongest support for serotonin’s inﬂ  uence on ejacula-
tory function derives from the observed clinical efﬁ  cacy of 
central selective seratonin reuptake inhibitors (SSRIs) in PE 
(Kim and Seo 1998; Waldinger et al 1998b). Seratoninergic 
neurons originate in the raphe nuclei and adjacent reticular 
formation of the brainstem (Waldinger 2005). After its Therapeutics and Clinical Risk Management 2007:3(2) 280
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production in the cell body, serotonin passes through the 
serotonergic neuron to the presynaptic membrane, where 
it is released into the synapse and acts on the postsynaptic 
receptors. By the action of serotonin transporters (5-HTT) 
on the presynaptic membrane, serotonin is returned to the 
presynaptic neuron. The process of serotonin release and its 
action on postsynaptic receptors is referred to as serotonergic 
neurotransmission (Waldinger 2005).
The involvement of central serotonergic neurotransmis-
sion in ejaculation has been investigated in a number of 
animal studies. The drug stimuli of the SSRIs ﬂ  uoxetine and 
paroxetine most closely resemble 5-HT2C receptor activation 
(Berendsen and Broekkamp 1994). The activation of both 
5-HT2A and 5-HT2C receptors by 2,5-dimethoxy-4-iodophe-
nyl-2-aminopropane increases ejaculatory latency (Foreman 
et al 1989), while the selective 5-HT2A receptor agonist 2,5-
dimethoxy-4-methylamphetamine does not exhibit this effect 
(Ahlenius et al 1981). On the other hand, selective activation 
of 5-HT1A receptors by 8-hydroxy-2-(di-n-ropylaminotetra-
lin) shortens the ejaculatory latency time and reduces the 
number of intromissions preceding ejaculation in animals 
(Ahlenius et al 1981). SSRIs block the 5-HT transporters, 
both in the presynaptic membrane and the cell-body. As a 
consequence, serotonin levels increase outside the cell-body 
and in the synapses (Waldinger 2005). Due to increased se-
rotonin levels by SSRIs, 5-HT1A autoreceptors at the surface 
of the cell-body and 5-HT1B autoreceptors in the presynaptic 
membrane become activated (Waldinger et al 1998a, 2005b).
The initial activation of both somatodendritic 5-HT1A auto-
receptors and the presynaptic 5-HT1B autoreceptors results 
in an inhibition of 5-HT release into the synaptic cleft. 
Consequently, after acute SSRI administration, serotonin 
concentrations in the synapse generally diminish, but may be 
active due to the blockage of the 5-HT transporters causing 
some slight stimulation of all postsynaptic 5-HT receptors 
(Waldinger et al 1998a, 2005b). However, after chronic SSRI 
administration, the 5-HT1A and 5-HT1B autoreceptors become 
desensitized, resulting in a diminished inhibitory action of 
these receptors to 5-HT release. Consequently, serotonin is 
again released into the synapse. 
Male rat studies have demonstrated that the neurotrans-
mitter serotonin and two 5-HT receptors are involved in the 
ejaculatory process (Ahlenius et al 1981; Foreman et al 1989). 
Activation of 5-HT2C receptors delays ejaculation, whereas 
activation of 5-HT1A receptors accelerates ejaculatory la-
tency (Ahlenius et al 1981). Based on these animal studies, 
Waldinger et al (1998a) hypothesized that lifelong PE is a 
neurobiological phenomenon related to decreased central 
serotonergic neurotransmission, caused by a disruption in 
the functional balance of 5-HT receptor subtypes: increased 
sensitivity of 5-HT1A receptors with decreased sensitivity of 
5-HT2C receptors. Hence, they suggest that treatment for PE 
should aim at 5-HT2C receptor stimulation and/or 5-HT1A 
receptor inhibition (Waldinger et al 2005b).
Animal studies for the treatment 
of PE
Development of new serotonergic drugs seems inevitable in 
light of the high incidence and the need for effective treatment 
of premature ejaculation. Thus, the development of an in vivo 
experimental model for objectively assessing the efﬁ  cacy of 
these new drugs is mandatory. Hsieh et al (1998) previously 
established a rat model involving electrical stimulation of the 
lesser splanchnic nerve to induce changes in the intraluminal 
pressure of the seminal vesicle. These investigators evaluated 
the impact of various agents, such as prazosin, 5-hydroxy 
tryptamine, clomipramine, fluoxetine, imipramine, and 
indatraline, on seminal vesicle pressure induced by electri-
cal stimulation. They documented concentration-dependent 
effects with prazosin and all serotonergic agents, but not with 
imipramine or indatraline. Fluoxetine was reported to have 
the highest efﬁ  cacy. On the other hand, Kim et al (2000) 
studied the effects of serotonergic drugs including clomip-
ramine, sertraline, paroxetine, and ﬂ  uoxetine on the vasal 
pressure induced by electrical stimulation of the hypogastric 
nerve (Kim et al 2000). All these serotonergic drugs were 
documented to cause concentration-dependent inhibition of 
intraluminal pressure elevation in the vas deferens. These 
investigators reported clomipramine as having the strongest 
inhibitory effect followed by sertraline, paroxetine, and 
ﬂ  uoxetine (Kim et al 2000).
Recently, Kim et al (2004) established an in vivo 
experimental model in which the intraluminal pressure 
responses of both the seminal vesicle and vas deferens 
could be measured simultaneously in a single animal. They 
stimulated the hypogastric nerve as it was more speciﬁ  c 
in action or distribution than the lesser splanchnic nerve 
in inducing contraction of the seminal tract by electrical 
stimulation. The basic hypothesis of this study was that 
drugs for the treatment of PE produce their effects by inhib-
iting intraluminal pressure elevations of the seminal tract. 
All serotonergic agents tested signiﬁ  cantly inhibited the 
increase in seminal vesicle pressure induced by hypogastric 
nerve stimulation. All serotonergic drugs were documented 
to exhibit signiﬁ  cant inhibitory effects on the contractile 
responses of the seminal vesicle, whereas minimal (ser-Therapeutics and Clinical Risk Management 2007:3(2) 281
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traline) to no effects (ﬂ  uoxetine and paroxetine) were 
observed in the vasal pressure responses. As 50%–70% of 
the ejaculatory volume is produced by the seminal vesicle, 
this organ is a greater contributor than the vas deferens in 
ejaculatory volume (Coffey 1988). Thus, the reasoning is 
that an inhibitory effect on seminal vesicle pressure is more 
important than the effect on vasal pressure.
In the human, electrical stimulation of either the presacral 
nerve (superior hypogastric ganglion) or hypogastric nerve 
causes contraction of the bladder neck, seminal vesicles, vas 
deferens, and ejaculatory ducts (Kim et al 2004). The mild 
delaying effect in humans of ﬂ  uvoxamine on ejaculation 
relative to paroxetine has been demonstrated in a placebo-
controlled male rat study using a chronic administration 
treatment model (Waldinger et al 1998b, 2002). However, 
this difference in the effects between these two agents has 
not been observed in the acute treatment model (Mos et al 
1999).
Treatment
Psychological/behavioral therapy
Behavioral therapy was ﬁ  rst advocated by Semans in 1956 
with the “squeeze technique” and later popularized in the 
1970s by Masters and Johnson. This technique involves 
withdrawal of the penis during intercourse prior to the mo-
ment of ejaculatory inevitability, and the partner is asked to 
apply a sharp squeeze to the glans to abort ejaculation. 
The stop-start technique has since been popularized by 
Kaplan in 1983. In this technique the man is asked to pause 
during sexual stimulation, just prior to impending ejacula-
tion. This pause allows the patient to acclimatize to the 
sensation and to condition himself to increased ejaculatory 
control. This technique helps the patient to heighten his 
awareness of sexual sensations. Unfortunately, many others 
have found that any initial success achieved by behavioral 
therapy was not maintained at 3-year follow-up (Sharlip 
2005). Non-pharmacological treatment options for PE are 
provided in Figure 1.
Topical anesthetics
A number of creams and gels are available that desensitize the 
penis and may in effect delay orgasm in men with PE. After 
a man applies one of these agents to his penis, he proceeds 
to sexual activity with or without use of a condom. If he 
removes the condom, he should wash the penis to remove any 
remaining compound, thus reducing or avoiding the chances 
of desensitizing or numbing his partner’s genitalia.
The use of topical anesthetic ointments is probably the 
oldest treatment for delaying ejaculation, but only a few con-
trolled studies gave been reported. In one study, the results 
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Figure 1 Non-pharmacological treatment options for PE.
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of lidocaine-prilocaine cream 10 minutes before intercourse 
were described (Berkovitch et al 1995). Also, an aerosol 
formulation of lidocaine-prilocaine is effective in prolonging 
IELT and in improving sexual satisfaction in men with PE 
and their partners. The main drawback of topical anesthetics 
is their potential to cause a reduction in penile sensation and 
vaginal numbness in his partner.
In Korea, positive results were reported with SS-cream, 
a regionally manufactured agent consisting of the extracts 
of nine natural herbal products proposed to decrease penile 
hypersensitivity and or hyperexcitability (Xin et al 1997; Choi 
et al 2000). These investigators examined the efﬁ  cacy of SS-
cream in a double blind, randomized, placebo-controlled study 
in 106 men with lifelong PE. During the screening phase of 
the study, the men’s mean IELT was 1.37 ± 0.12 minutes and 
both the men and their partners reported being dissatisﬁ  ed 
with their sexual lives (Choi et al 2000). During the treatment 
phase, which consisted of 6 separate applications (one of which 
was a placebo), the men applied the cream to the glans penis 1 
hour before intercourse. After treatment the men’s mean IELT 
increased to 2.45 ± 0.29 minutes with placebo and to 10.92 
± 0.29 minutes with use of SS-cream. Side-effects included 
local burning and mild pain, which was reported in 18.49% 
of the 530 active treatment applications, but these symptoms 
disappeared in less than 1 hour. No adverse effects on sexual 
function or systemic side-effects were noted.
SSRIs
SSRIs are widely used pharmacotherapeutic agents. The 
potential of antidepressants to treat PE was ﬁ  rst introduced 
by Ahlenius et al (1981). This group showed that the tricyclic 
antidepressant clomipramine prolonged ejaculatory latency 
in rats by blocking central serotonin reuptake. However, as 
postsynaptic 5-HT1C receptors are minimally stimulated after 
a few hours of SSRI administration, it can be predicted that 
on-demand SSRI treatment will have only a slight ejacula-
tion-delaying effect (Waldinger 2005). The absence of a 
signiﬁ  cant ejaculation delay after acute SSRI administration 
has been demonstrated in animal sexual behavioral studies 
(Mos et al 1999).
Although, many studies have been published on the 
use SSRIs in the treatment of PE, Waldinger et al were the 
ﬁ  rst to evaluate these studies methodologically in light of 
evidence-based criteria (Waldinger 2003; Waldinger et 
al 2004b). The results revealed that from 79 publications 
on drug treatment of PE, 35 studies involved serotonergic 
antidepressants. He clearly documented that in both single-
blind and open-design studies, as well as studies using a 
questionnaire or subjective report on ejaculation time, there 
was a high variability, and that there was over-estimated 
responses in the degree of ejaculatory delay. Only 8 studies 
(18.5%) fulﬁ  lled all criteria of evidence-based medicine, eg, 
double-blind studies prospectively using real-time stopwatch 
assessments at each intercourse both at baseline and during 
the drug trial (Waldinger 2003, 2005; Waldinger et al 2004b). 
For daily treatment, a rank order of efﬁ  cacy of the SSRIs was 
established, with clomipramine being the best, followed by 
paroxetine, sertraline, and ﬂ  uoxetine.
In a double-blind stopwatch study in men with lifelong 
PE associated with an IELT of less than 1 minute, Waldinger 
et al (2004a) found that on-demand treatment with 20 mg 
paroxetine exerted only a 1.41-fold increase in IELT at a 
drug coitus interval time (DCIT) of 5.30 hours (Waldinger 
et al 2004a). The calculated 1.41-fold increase means that 
on-demand treatment with 20 mg paroxetine induced only 
a 40% ejaculation delay. The degree of ejaculation delay 
in this study was considered as clinically insigniﬁ  cant by 
the men and their female partners. On the other hand, on-
demand treatment with 25 mg clomipramine with a mean 
DCIT of 5.15 hours led to a 4.05-fold increase in the IELT, 
which was considered as clinically relevant by the couples, 
and conﬁ  rmed earlier reports on the efﬁ  cacy of on-demand 
clomipramine treatment (Segraves et al 1993; Haensel et al 
1996; Waldinger et al 2004a).
Interestingly, other studies on paroxetine on-demand use 
for PE demonstrated stronger ejaculatory-delaying effect 
(McMahon and Touma 1999; Abdel-Hamid et al 2001). In 
the ﬁ  rst study, Abdel-Hamid et al (2001) reported a 4-fold 
ejaculation delay with on-demand 20 mg paroxetine, admin-
istered 3–4 hours prior to coitus. Similarly, McMahon and 
Touma (1999), using a single-blinded design, reported an 
11-fold ejaculation delay without remarkable serotonergic 
side-effects, with 20 mg paroxetine administered 3–4 hours 
before coitus. However, such a strong delay with on-demand 
treatment in the absence of serotonergic side-effects does not 
seem likely, as this implies better effects with on-demand 
treatment than previously reported daily treatment with 20 mg 
paroxetine (Waldinger 2005). As an absence of ejaculation 
delay with acute SSRI administration has been demonstrated 
in a number of animal sexual behavioral studies and based 
on current knowledge with conventional SSRIs, it is unlikely 
that on-demand use of SSRIs will delay ejaculation within 
1–2 hours of intake (Mos et al 1999; Waldinger 2005). Based 
on animal studies, Waldinger et al (2005b) postulated that 
on-demand treatment of PE with conventional SSRIs will 
only be successful when an SSRI is combined with a 5-HT1A Therapeutics and Clinical Risk Management 2007:3(2) 283
Management of PE with dapoxetine
receptor antagonist, or another serotonergic intervention that 
acutely stimulates serotonergic release. 
For these reasons, daily administration of the SSRIs 
seems the likely choice for the treatment of PE. After a few 
weeks, as the 5-HT1A and 5-HT1B autoreceptors become 
desensitized, serotonin is increased in the synapse region 
(Waldinger 2005). With SSRI-induced blockage of the 5-HT 
transporters, serotonin cannot return to the presynaptic neu-
ron, and as a consequence, serotonin levels in the synapse 
rise. It is the activity of the postsynaptic receptors that ulti-
mately determines the clinical effects of daily administration 
of SSRIs (Waldinger 2005).
Studies on the use of various SSRIs are summarized in 
Table 1.
Type 5 phosphodiesterase (PDE-5) 
inhibitors 
Recently several studies have suggested that sildenaﬁ  l may be 
beneﬁ  cial in the treatment of PE, either as a single agent or in 
combination with SSRIs. In the study by Abdel-Hamid et al 
(2001), 31 patients with lifelong PE underwent treatments 
with clomipramine, sertraline, and paroxetine, the squeeze 
technique, or sildenaﬁ  l in a randomized crossover design. 
Sildenaﬁ  l was administered as needed 3–5 hours before 
planned sexual intercourse. The authors reported that silde-
naﬁ  l was superior to all of the SSRIs and the pause-squeeze 
technique in terms of IELT and sexual satisfaction score. In 
another study, Chen et al (2001) investigated the efﬁ  cacy of 
sildenaﬁ  l in the treatment of severe PE in 58 men who failed 
other treatment modalities, such as behavioral therapy, topi-
cal lidocaine, tricyclic antidepressants, and SSRIs. Sildenaﬁ  l 
was taken 1 hour before sexual activity in escalating dosing 
from 25 to 100 mg until satisfactory ejaculation was attained. 
The authors concluded that sildenaﬁ  l was useful in the treat-
ment of PE for patients who have failed other remedies. 
In an extension to the previous study, Chen et al (2003) 
reported that sildenaﬁ  l plus paroxetine had a higher success 
rate (90%) than paroxetine alone in patients with severe PE. 
The therapeutic protocol involved taking paroxetine 20 mg 
7 hours before sexual intercourse and sildenaﬁ  l 25–100 mg 
1 hour before sexual activity.
Recently, in a well-designed study, Salonia et al (2002) 
compared paroxetine alone with paroxetine and sildenaﬁ  l 
as an oral therapy for men reporting PE. In the combina-
tion group, paroxetine was given as 10 mg once daily for 
20 days, followed by 20 mg as needed and sildenaﬁ  l 50 mg 
1 hour before sexual activity. This study demonstrated that 
the combination of paroxetine and sildenaﬁ  l obtained better 
results in regards to IELT and intercourse satisfaction than 
paroxetine alone. The combination treatment was associated 
with a mild increase in drug-related adverse events, such as 
headache (20%), nausea (15%), and ﬂ  ushing (15%). Despite 
the higher incidence of adverse effects associated with the 
combined therapy, most patients (90%) were willing to 
continue this treatment on an as-needed basis.
Another study that included 38 patients with secondary 
PE who were treated with sildenaﬁ  l 50–100 mg alone found 
signiﬁ  cant improvement in sexual satisfaction score and 
prolongation of mean IELT in 95% of participants (Lobik 
et al 2003). The most recent combination study compared 
Table 1 Doses and adverse effects of selective and nonselective serotonin reuptake inhibitors for treatment of PE
Antidepressanta  Recommended dose  IELT increase   Side-effects  % side-effects
   from  baseline
   ( ≈1 minutes)
Clomipramine  25–50 mg/d or 25 mg   3–6 minutes  Dry mouth, drowsiness,   60%
(Anafranil®)  4–24 hours pre-intecourse    reduced potency, nausea,
     vomiting,  other
Fluoxetine  5–20 mg/d  2–9 minutes  Drowsiness, dry mouth,   35%
(Prozac®,       anejaculation, reduced 
Sarafem®)     potency,  nausea
Paroxetine (Paxil®)  10–40 mg/d or 20 mg   3–10 minutes  Anejaculation, nausea,   15–65%
  3–4 hours pre-intercourse    reduced libido, anorexia,
     drowsiness,  sensory 
     confusion
Sertraline (Zoloft®)  25–200 mg/d or 50 mg   3–6 minutes  Drowsiness, dry mouth,   30%
  4–8 hours pre-intercourse    anejaculation, reduced 
     potency,  nausea
Derived from McMahon (1998), Kara et al (1996), Waldinger et al (1994), Strassberg et al (1999, 2005), Eli Lilly (2005), GlaxoSmithKline (2005), Pﬁ  zer, Inc (2005).
aThe compounds are ordered alphabetically.
Abbreviations: IELT, intravaginal ejaculatory latency time; PE, premature ejaculation.Therapeutics and Clinical Risk Management 2007:3(2) 284
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sildenaﬁ  l 25–100 mg plus sertraline 50 mg (48 patients) 
versus sertraline 50 mg alone (51 patients) and sildenaﬁ  l 50 
mg alone (30 patients) in 3 different groups of PE patients 
(Lazona and Castane 2003). The highest success rate was 
observed in the group receiving sertraline plus sildenafil 
(62.5%) followed by those receiving sertraline alone 
(56.8%), and lastly those who received sildenafil alone 
(40%).
There are several possible mechanisms that can explain 
the efﬁ  cacy of sildenaﬁ  l in the treatment of PE. Sildenaﬁ  l 
may inhibit the contractile responses of the seminal vesicles, 
vas deferens, prostate, urethra, and even the skeletal muscles. 
Expression of PDE activity has been reported in the prostate, 
seminal vesicle, and skeletal muscles (Djoseland et al 1980; 
Stacey et al 1998; Yanaka et al 1998; Uckert et al 2001). PDE 
expression in vas deferens has not been studied yet; however, 
nitrergic innervation and nitric oxide synthase (NOS) activ-
ity have been localized to the human vas deferens, seminal 
vesicle, prostate, urethra, and skeletal muscles (Dixon and 
Jen 1995; Jen and Dixon 1995; Hedlund et al 1997; Jen et al 
1997). In addition, evidence suggests that nitric oxide (NO) 
is the predominant inhibitory (relaxatory) neurotransmitter 
in the genitourinary organs (Naseem et al 2000; Andersson 
2001). In male rats, NO and NO-donator agents were reported 
to inhibit seminal emission (Hull et al 1994). Furthermore, 
NO inhibitors increase the number of ex-copula seminal 
emissions and decrease the latency to seminal emission in 
the rat (Bialy et al 1996).
In animal studies, the cyclic nucleotides cyclic adenosine 
monophosphate (cAMP) and/or cyclic guanosine monophos-
phate (cGMP) relax the smooth muscle of the rat and guinea 
pig vas deferens (Schultz et al 1977; Stjarne et al 1979; 
Kato et al 2000). Sildenaﬁ  l has been shown to cause potent 
and selective potentiation of nitrergic transmission in the 
urogenital muscles in male mice (Frith and Gibson 2000). 
As human seminal vesicle smooth muscle relaxation and 
modulation of ejaculation were reported to be regulated, in 
part, by increases of intracellular cGMP (Stjarne et al 1979). 
It is interesting to speculate on PDE-5 inhibitor action in 
this part of the body.
PDE-5 inhibitors are also postulated to inhibit adrenergic 
transmission in accessory sex organs (Takeda et al 1995). In 
in vitro studies, sildenaﬁ  l inhibits adrenergic neurotransmis-
sion in the human vas deferens (Medina et al 2000). Further-
more, NO-donator agents diminish the adrenergic response 
in human seminal vesicles in vitro (Machtens et al 2003). 
Recently, sildenaﬁ  l has been documented to exhibit a direct 
inhibitory action on smooth muscles tone of the human vas 
deferens, through activation of prejunctional K+ channels 
(Medina et al 2000).
Sildenafil has also been shown to induce a state of 
peripheral analgesia via activation of the NO/cGMP signal-
ing pathway in animals (Jain et al 2001). This effect could 
be instrumental in alleviating the penile hypersensivity that 
is reported in some patients with PE and may in turn mimic 
the success of topical anesthetics in the treatment of some 
PE patients (Berkovitch et al 1995). 
Sildenaﬁ  l has been reported to cause a clinically signiﬁ  -
cant improvement in the total duration of erections during 
visual sexual stimulation when evaluated with sexual func-
tion questionnaires and Rigiscan devices (Boolell et al 1996; 
Sadovsky et al 2001). Because the ejaculatory latency time 
may be dependent on the duration of erection, any increase 
in the duration of erection may in turn prolong the ejacula-
tory latency time (Kameya et al 1997). In this regard, it is 
recognized that sildenaﬁ  l may conceivably increase the 
ejaculatory latency time and contribute to prolongation of 
ejaculation.
Other PDE-5 inhibitors (tadalaﬁ  l and vardenaﬁ  l) have 
been evaluated for treatment of PE. Mattos and Lucon (2005) 
evaluated tadalaﬁ  l alone and in combination with ﬂ  uoxetine 
in 84 PE patients without ED. The patients were randomly 
assigned in a double-blind manner into 4 groups: (1) tadalaﬁ  l 
20 mg and ﬂ  uoxetine 90 mg, (2) tadalaﬁ  l 20 mg and placebo, 
(3) ﬂ  uoxetine 90 mg and placebo, and (4) two different 
placebo capsules. Fluoxetine 90 mg or placebo was given 
once a week, and tadalaﬁ  l 20 mg or placebo was given in a 
36-hour frame of intended sexual intercourse. Mean baseline 
IELT was 55 seconds with stopwatch, and was not different 
between groups. The greatest increase from baseline IELT 
was observed in patients in the tadalaﬁ  l plus ﬂ  uoxetine group, 
followed by the ﬂ  uoxetine only group, and the tadalaﬁ  l-only 
group, respectively. This study demonstrates that tadalaﬁ  l 20 
mg once in 36 hours in combination with ﬂ  uoxetine 90 in 
a slow-release form taken weekly can signiﬁ  cantly increase 
IELT.
Sommer et al (2005) compared vardenaﬁ  l 10 mg (30 
minutes pre-intercourse) and sertraline 50 mg (4 hours pre-
intercourse) in a prospective, randomized, cross-over study. 
Ejaculation was assessed with IELT using a stopwatch and 
graded on a scale of 0 to 8 (0 = almost never, 8 = almost 
always). The degree of improvement in ejaculation grade was 
2.9 with vardenaﬁ  l and 1.86 with sertraline, and the increases 
in IELT were 5.23 in vardenaﬁ  l-treated patients and 2.87 in 
sertraline-treated patients. This study suggests that there is 
a potential for vardenaﬁ  l in the treatment of PE.Therapeutics and Clinical Risk Management 2007:3(2) 285
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Dapoxetine
Although SSRIs are intended for chronic use in the treatment 
of depression and are designed to have pharmacokinetic 
proﬁ  les that would allow them to provide constant systemic 
concentration with long-term administration, they may need 
days to weeks to reach a maximum steady-state concentra-
tion in order to exhibit efﬁ  cacy (Hiemke and Hartter 2000). 
Therefore, SSRIs are commonly used in a daily dosing 
schedule for the treatment of PE (Montague et al 2004). In 
addition to the potentially desirable side-effect of delaying 
ejaculation, this dosing regimen for long-acting SSRIs is 
associated with a number of undesirable side-effects, such 
as decreased libido and ED (Montague et al 2004). With the 
success of daily SSRI use in delaying ejaculation, it has been 
suggested that on-demand treatment with SSRIs possessing a 
short half-life and short Tmax would be equally effective, more 
convenient, and exhibit fewer serotonergic side-effects than 
observed with daily treatment (Waldinger 2005). Therefore, 
an ideal compound for the treatment of PE should exhibit 
pharmacokinetic proﬁ  les having rapid absorption, adequate 
availability to establish therapeutic exposure at the target 
site, and rapid elimination to reduce total drug exposure and 
minimize the incidence of side-effects (Modi et al 2006).
Dapoxetine, ((+)-(S)-N,N-dimethyl-(a)-[2-(1-
naphthalenyloxy)ethyl]-benzenemethanamine hydrochlo-
ride) is a novel potent serotonin transport inhibitor with a 
unique pharmacokinetic proﬁ  le, and is currently in develop-
ment for use in the treatment of PE (Dresser et al 2004; Gengo 
et al 2005). Dapoxetine hydrochloride is a water-soluble 
powder with a molecular weight of 341.88 and has a pKa 
of 8.6 and is mainly charged at a physiological pH. These 
pharmacological characteristics allow for rapid distribution 
in the body and are different from the pharmacokinetics 
observed in conventional SSRIs. Dapoxetine is a fast-acting 
compound that attains its peak plasma concentration in about 
1.5 hours after dosing, which is much faster than ﬂ  uoxetine, 
paroxetine, or sertraline (Strassberg et al 1999, 2005; Eli 
Lilly 2005; GlaxoSmithKline 2005; Pﬁ  zer 2005). After oral 
administration, dapoxetine is readily absorbed, followed by 
a rapid decline in plasma concentrations. These pharmaco-
kinetic properties make dapoxetine an excellent candidate 
for on-demand dosing, which avoids the potential disadvan-
tages of continuous pharmacotherapy. The pharmacokinetic 
characteristics of dapoxetine compared with paroxetine and 
sertraline are provided in Table 2.
Although the pharmacological action of dapoxetine is 
similar to that of clomipramine and conventional SSRIs, the 
chemical structure and pharmacokinetic proﬁ  le of dapox-
etine differentiates it from other SSRIs. Dapoxetine is not 
a halogenated compound, whereas others contain one or 
more halogen atoms. The molecular structure of dapoxetine 
also includes a naphthyl moiety and it is possible that these 
features underpin the physicochemical and pharmacokinetic 
properties of the molecule.
Dapoxetine is a potent inhibitor of the 5-HT reuptake 
transporter. Studies conducted in cells expressing the hu-
man transcript of the 5-HT, norepineprine, and dopamine 
reuptake reporters to determine the inhibition constant (Ki) 
and the activity of dapoxetine (IC50) values showed that 
dapoxetine competed in a concentration-dependent man-
ner for speciﬁ  c [3H]citalopram binding sites on the 5-HT 
reuptake transporter (Ki = 9.5), speciﬁ  c [3H]nisoxatine 
binding sites on the norepinephrine reuptake transporter 
(Ki = 6.6), and speciﬁ  c [3H]WIN35428 binding sites on the 
dopamine reuptake transporter (Ki = 5.8) (Gengo et al 2005). 
Additionally, dapoxetine inhibited the uptake of [3H]5-HT 
by the 5-HT reuptake transporter with a value of 1.12 nM, 
whereas the uptake of [3H]norepinephrine into cells utiliz-
ing the norepinephrine reuptake transporter and uptake of 
[3H]dopamine by the dopamine reuptake transporter were 
inhibited by dapoxetine with IC50 values of 202 nM and 
1720 nM, respectively. In conclusion, dapoxetine binds 
to 5-HT, norepinephrine, and dopamine reuptake trans-
porters and inhibits 5-HT, norepinephrine, and dopamine 
uptake with an order of potency: 5-HT > norepinephrine 
>> dopamine.
A double-blind, randomized, placebo-controlled, cross-
over, 3-period phase II US study of dapoxetine for the 
treatment of PE, comparing the safety and efﬁ  cacy of on-
demand dapoxetine 60 mg versus 100 mg versus placebo 
was presented (Hellstrom 2004). Each of the three 2-week 
treatment periods was separated by a 72-hour washout pe-
riod. The patients enrolled in the study were all heterosexual 
Table 2 Pharmacokinetic characteristics of dapoxetine 
compared with paroxetine and sertraline 
 Dapoxetine  Paroxetine  Sertraline
Dose (mg)  60  40  100
Cmax (ng/mL)  386.0  19.0  22.7
Tmax (h)  1.5  6.83  6.4
T1/2a (h)  1.03  3.93  3.57
T1/2b (h)  21.9  46.7  39.5
C24 (% of peak)  3.67  45.1  47.8
Accumulation 1.3  2.45  2.68
Derived from Gengo et al (2005), Hellstrom (2004), Hellstrom et al (2005), Anders-
son et al (2006). Therapeutics and Clinical Risk Management 2007:3(2) 286
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men aged 18–65 years who had been involved in a stable, 
monogamous relationship for at least 6 months and whose 
baseline IELT was under 2 minutes, as measured by the 
partner using a stopwatch. The primary endpoint was IELT, 
as well as patients’ satisfaction control over ejaculation. A 
total of 130 men with PE completed the study. The mean 
baseline IELT increased from 1.01 minutes to 2.94 minutes 
with 60 mg dapoxetine, 3.20 minutes with 100 mg dapox-
etine, and 2.05 minutes with placebo (p < 0.0001 vs placebo). 
Patients who received the 60-mg dose of dapoxetine reported 
signiﬁ  cant increases in their control over ejaculation from 
baseline (p < 0.0001) and signiﬁ  cant beneﬁ  ts in their sexual 
satisfaction (with their sexual intercourse episodes). Nausea, 
the most common reported adverse effect, occurred in 5.6% 
of patients who received 60 mg, 16.1% of those who received 
100 mg, and 0.7% of those who received placebo (Table 3) 
(Hellstrom 2004). Of the 10 patients who discontinued the 
study because of side-effects, 9 were receiving the 100-mg 
dose of dapoxetine and 1 patient was receiving placebo. 
Another two phase II clinical trials investigated the ef-
ﬁ  cacy and tolerability of 20, 40, 60, and 100 mg dapoxetine 
in order to determine the appropriate on-demand doses of 
dapoxetine for further study in large-scale phase III clinical 
trials (Hellstrom et al 2005). Both double-blind, multi-center, 
randomized, placebo-controlled, 3-period cross-over phase II 
studies enrolled men with PE, based on DSM-IV-TR criteria 
and IELT. Subjects were instructed to take study drug prior 
to the anticipated sexual intercourse (1–3 hours prior in 
study 1, and 1–2 hours prior in study 2) and to attempt sexual 
intercourse ≥ twice weekly. The primary endpoint was IELT 
measured with a stopwatch held by the female partner. In 
study 1, 128 of 157 patients (20 mg and 40 mg dapoxetine), 
and in study 2, 130 of 166 (60 mg and 100 mg dapoxetine) 
randomized subjects completed the trials. All four doses of 
dapoxetine documented statistically signiﬁ  cant improve-
ments in IELT over placebo (Table 4).
In a recent study by Pryor et al (2005), the efﬁ  cacy 
and tolerability of dapoxetine in the treatment of PE were 
evaluated. Men with PE (n = 2614) as deﬁ  ned by DSM-IV-
TR criteria were enrolled in 2 randomized, double-blind, 
placebo-controlled, multi-center, phase III clinical trials of 
identical design, and each had a 2-week baseline period and 
12-week treatment period. At the end of the baseline period, 
subjects with mean IELT ≥ 2 minutes were randomized 1:1:1 
to placebo, dapoxetine 30 mg, or 60 mg, and instructed to 
take the study drug 1–3 hours prior to anticipated sexual in-
tercourse. The primary efﬁ  cacy endpoint was IELT adjusted 
for baseline, as measured by a stopwatch held by the female 
partner. Secondary endpoints were subjective perception of 
Control Over Ejaculation and Satisfaction With Sexual In-
tercourse, and were assessed at baseline, 4, 8, and 12 weeks, 
and rated on 5-point scales of between 0 (very poor) and 4 
(very good). Preliminary results of this study demonstrated 
that there were signiﬁ  cant differences between placebo 
and each active treatment group in mean IELT, Control 
Over Ejaculation, and Satisfaction With Sexual Intercourse 
(p < 0.0001). Changes from baseline to study end point 
for mean IELT were 0.90–1.75 min (placebo), 0.92–2.78 
minutes (30 mg dapoxetine), and 0.91–3.32 minutes (60 mg 
dapoxetine). Both dapoxetine 30 mg and 60 were found to 
be more effective than placebo in increasing IELT on ﬁ  rst 
dose. Treatment-related side-effects (incidence ≥5%) with 
both 30 mg and 60 mg dapoxetine were nausea (8.7% and 
20.1%), headache (5.9% and 6.8%), diarrhea (6.8% with 
60 mg), and dizziness (6.2% with 60 mg). Discontinuation 
rates due to adverse effect were reported as 0.0%, 4%, and 
10% for placebo, 30 mg, and 60 mg doses of dapoxetine, 
respectively. The authors concluded that dapoxetine 30 mg 
or 60 mg is effective for the on-demand treatment of PE, 
with increased IELT, improved Control Over Ejaculation, 
and increased Satisfaction With Sexual Intercourse.
The use of ethanol and PDE-5 inhibitors with sexual 
activity is recognized. The interactions of dapoxetine with 
PDE-5 inhibitors and ethanol have also been investigated. 
The effects of PDE-5 inhibitors on the pharmacokinetics 
of dapoxetine were studied in a randomized, open-label, 
Table 3 Adverse events observed with dapoxetine (60 mg and 
100 mg) and placebo 
Adverse effects  Placebo  Dapoxetine   Dapoxetine 
  (n = 140)  60 mg  100 mg
    (n = 139)  (n = 145)
Total # of pts 1 AE  21 (15.0%)  41 (29.5%)  57 (39.3%)
Nausea  1 (0.7%)  8 (5.8%)  24 (16.6%)
Headache  0  6 (4.3%)  8 (5.5%)
Upper respiratory 
tract infection  1 (0.7%)  3 (2.2%)  2 (1.4%)
Diarrhea  1 (0.7%)  7 (5.0%)  10 (6.9%)
Dizziness  0  3 (2.2%)  2 (1.4%)
Rhinitis  1 (0.7%)  6 (4.3%)  1 (0.7%)
ED 0  0  2  (1.4%)
Somnolence  1 (0.7%)  4 (2.9%)  2 (1.4%)
Insomnia  1 (0.7%)  5 (3.6%)  9 (6.2%)
Dyspepsia  0  4 (2.9%)  3 (2.1%)
Nervousness  0  5 (3.6%)  5 (3.4%)
Dropouts 1 0  9
Derived from Hellstrom (2004), Hellstrom et al (2005).
Abbreviations: AE, adverse events; ED, erectile dysfunction.Therapeutics and Clinical Risk Management 2007:3(2) 287
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3-period crossover study in healthy male subjects (n = 24; 
18–45 years of age) receiving a single 60-mg dose of dapox-
etine, dapoxetine 60 mg plus sildenaﬁ  l 100 mg, and dapox-
etine 60 mg plus tadalaﬁ  l 20 mg (Dresser et al 2006). Each 
treatment was separated by a 6- to 14-day washout period. 
Blood samples were collected predose and at speciﬁ  ed times 
after dosing for measurement of dapoxetine and its metabo-
lites and tadalaﬁ  l and sildenaﬁ  l plasma concentrations. This 
study demonstrated that sildenaﬁ  l and tadalaﬁ  l did not have a 
clinically signiﬁ  cant effect on the pharmacokinetics of dapox-
etine. In the other study that was designed as double-blind, 
randomized, and 4-period crossover in healthy male adult 
subjects, the effect of ethanol on the pharmacokinetics of 
dapoxetine was investigated (Modi et al 2005). Each separate 
treatment period of a single dose of dapoxetine 60 mg and a 
single dose of 0.5 g/kg ethanol, dapoxetine 60 mg and ginger 
ale (placebo for ethanol), placebo (for dapoxetine) and 0.5 
g/kg ethanol, and placebo for both drugs was administered 
with a 5- to 21-day washout period. Safety was assessed by 
adverse event reporting throughout the study and by labora-
tory tests, and blood samples were collected predose and at 
speciﬁ  ed times after for measurement of plasma concentra-
tions of dapoxetine and its metabolites and ethanol analysis. 
The results of this study demonstrated that co-administra-
tion of ethanol with dapoxetine did not produce signiﬁ  cant 
changes in dapoxetine pharmacokinetics.
Conclusions
Neurobiological studies in animals and humans have pro-
vided better understanding of the physiology of ejaculation 
and pathophysiology of PE. The nature of PE is such that 
patients should not have to chronically take potent psychoac-
tive drugs, with long-lasting actions and debilitating side-ef-
fects. Dapoxetine is a selective serotonin transport inhibitor 
with unique pharmacokinetic and pharmocodynamic proper-
ties that account for its clinical effects. Future studies may 
demonstrate whether dapoxetine could possess many of the 
attributes of an ideal compound for the treatment of PE.
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